JPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/InstinetMarch 15, 2018 1:45 PM Alexion Pharmaceuticals (ALXN) PT Raised to $160 at BairdMarch 15, 2018 12:14 PM Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond JamesMarch 15, 2018 12:13 PM RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 ResultsMarch 15, 2018 9:41 AM Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMOMarch 15, 2018 8:57 AM S&P falls for fourth day as Mueller subpoena weighsMarch 15, 2018 7:47 AM Alexion (ALXN) Reports Positive Top-Line Results Showing Successful Phase 3 Study of ALXN1210 in Complement Inhibitor Treatment-Naive Patients with PNHMarch 15, 2018 6:31 AM Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)March 15, 2018 6:30 AM